
Quarterly report 2024-Q2
added 08-13-2024
TRACON Pharmaceuticals Market Cap 2011-2026 | TCON
As of April 06, 2026 TRACON Pharmaceuticals has a market cap of $ 46.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap TRACON Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.89 M | 31 M | 47.8 M | 105 M | 12.9 M | 21.8 M | 49.6 M | 60.9 M | 84.9 M | 113 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 113 M | 5.89 M | 53.2 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aquestive Therapeutics
AQST
|
467 M | $ 4.12 | -0.36 % | $ 441 M | ||
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 8.32 | 3.67 % | $ 228 M | ||
|
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 23.65 | 0.08 % | $ 3.01 B | ||
|
BioVie
BIVI
|
2.44 M | $ 1.46 | 2.82 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
62.9 B | $ 91.44 | 0.29 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
BioXcel Therapeutics
BTAI
|
15.4 M | $ 1.16 | -2.12 % | $ 14.2 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Burford Capital Limited
BUR
|
2.09 B | $ 4.52 | 9.18 % | $ 683 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Cabaletta Bio
CABA
|
283 M | $ 3.1 | 4.56 % | $ 311 M | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.17 | 1.44 % | $ 6.9 B | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
Catalyst Biosciences
CBIO
|
999 M | $ 19.48 | 0.39 % | $ 1.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Codexis
CDXS
|
111 M | $ 1.95 | 6.87 % | $ 170 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 3.01 | 0.67 % | $ 257 M | ||
|
Cerus Corporation
CERS
|
496 M | $ 1.91 | 2.69 % | $ 364 M | ||
|
Cullinan Management
CGEM
|
898 M | $ 15.11 | 4.71 % | $ 910 M | ||
|
Coherus BioSciences
CHRS
|
226 M | $ 1.72 | -0.87 % | $ 201 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
28.2 M | $ 0.46 | -13.02 % | $ 5.27 M | ||
|
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
CNS Pharmaceuticals
CNSP
|
1.06 M | $ 2.25 | -0.44 % | $ 998 K | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
3.04 B | $ 24.95 | 1.05 % | $ 3.05 B | ||
|
Celldex Therapeutics
CLDX
|
2.04 B | $ 31.33 | 0.85 % | $ 2.08 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 10.27 | 0.98 % | $ 137 M | ||
|
Cardiff Oncology
CRDF
|
116 M | $ 1.6 | 1.27 % | $ 107 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M |